UW coronavirus vaccine shows strong immune response in monkeys, mice

The University of Washington and Seattle-based HDT Bio Corp. announced the development of a promising COVID-19 vaccine candidate that uses a cutting-edge approach. Based on preliminary studies, HDT Bio has taken steps toward garnering FDA approval for phase one human trials, planned for late 2020.  

READ THE STORY at The Seattle Times »